ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
122.098,09
-0,50%
S&P 500
5.277,51
0,80%
US Dollar vs BRL
5,2457
-0,01%
Bitcoin
69.038,62
1,90%
Brent Oil
81,25
0,55%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. FS Development Corporation II (FSII)

  7. FS Development Corporation II (FSII) Notícias

FSII

FS Development Corporati... (FSII)

FS Development Corporation II
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:FSII
DataHoraFonteTítuloCódigoCompanhia
05/06/202317:03Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:FSIIFS Development Corporation II
02/06/202317:14Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:FSIIFS Development Corporation II
05/05/202317:06Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:FSIIFS Development Corporation II
21/04/202317:28Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:FSIIFS Development Corporation II
20/04/202308:54Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:FSIIFS Development Corporation II
20/04/202308:50Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:FSIIFS Development Corporation II
14/03/202317:07Edgar (US Regulatory)Annual Report (10-k)NASDAQ:FSIIFS Development Corporation II
14/02/202319:07Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:FSIIFS Development Corporation II
23/01/202318:23Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:FSIIFS Development Corporation II
23/01/202308:03Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:FSIIFS Development Corporation II
18/01/202318:08Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:FSIIFS Development Corporation II
16/09/202217:05Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:FSIIFS Development Corporation II
26/04/202207:16Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:FSIIFS Development Corporation II
07/02/202218:02Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:FSIIFS Development Corporation II
28/01/202218:46Edgar (US Regulatory)Securities Registration Statement (s-1/a)NASDAQ:FSIIFS Development Corporation II
21/01/202218:29Edgar (US Regulatory)Securities Registration Statement (s-1)NASDAQ:FSIIFS Development Corporation II
30/12/202118:31Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:FSIIFS Development Corporation II
27/12/202109:00GlobeNewswire Inc.Pardes Biosciences Debuts as a Publicly Traded Company Focused on Oral Antiviral Therapies to Potentially Treat and Prevent COVID-19NASDAQ:FSIIFS Development Corporation II
23/12/202115:12Edgar (US Regulatory)Amended Securities Registration (section 12(b)) (8-a12b/a)NASDAQ:FSIIFS Development Corporation II
23/12/202113:16Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:FSIIFS Development Corporation II
21/12/202109:00Business WireFSII and Pardes Biosciences Move Towards Merger With the Goal of Tackling COVID-19 via an Oral Antiviral for Treatment and Prevention of SARS-CoV-2 InfectionsNASDAQ:FSIIFS Development Corporation II
01/12/202113:38Business WireFS Development Corp. II Announces Effectiveness of Registration Statement for Proposed Business Combination with Pardes Special Meeting Scheduled for December 23, 2021NASDAQ:FSIIFS Development Corporation II
23/11/202118:53Edgar (US Regulatory)Registration Statement for Securities to Be Issued in Business Combination Transactions (s-4/a)NASDAQ:FSIIFS Development Corporation II
23/11/202118:38Edgar (US Regulatory)Amended Quarterly Report (10-q/a)NASDAQ:FSIIFS Development Corporation II
26/08/202109:00GlobeNewswire Inc.Pardes Biosciences Initiates First-in-Human Trial for PBI-0451, an Oral Antiviral in Development to Treat and Prevent SARS-CoV-2 InfectionsNASDAQ:FSIIFS Development Corporation II
05/08/202108:00GlobeNewswire Inc.Pardes Biosciences Appoints Deborah M. Autor, J.D. and Laura J. Hamill to Board of DirectorsNASDAQ:FSIIFS Development Corporation II
29/06/202107:00Business WirePardes Biosciences & FS Development Corp. II Announce Merger Agreement Creating Publicly Listed Biopharmaceutical Company Adv...NASDAQ:FSIIFS Development Corporation II
16/02/202123:36Business WireFS Development Corp. II, Sponsored by Foresite Capital, Announces Pricing of Upsized $175 Million Initial Public OfferingNASDAQ:FSIIFS Development Corporation II
11/10/201217:54Edgar (US Regulatory)Current report filing (8-K)NASDAQ:FSIIFS Development Corporation II
11/10/201217:49Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (SC 14D9/A)NASDAQ:FSIIFS Development Corporation II
 Apresentando as notícias mais relevantes sobre:NASDAQ:FSII

Seu Histórico Recente

GATE
LBKUSDT
LBank
EU
FRSG00014RF4
SG Issuer Sg Issuer Mc M...
BIT
UB8KNM
Unicredit Bank
BIT
Q00513
Leonteq Securities
AMEX
JPLD
JPMorgan Limited Duratio...
USOTC
FMNJ
Franklin Mining (PK)
LSE
FEME
Em Qi Etf
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados